Table 1.
Characteristics of patients
| Variables | All patients
|
Propensity score-matched patients
|
||||
|---|---|---|---|---|---|---|
| Monotherapy group (N=31) | Con-therapy group (N=34) | P-value | Monotherapy group (N=24) | Con-therapy group (N=24) | P-value | |
|
| ||||||
| Gender | 0.264 | 1.000 | ||||
| Male | 23 | 29 | 20 | 20 | ||
| Female | 8 | 5 | 4 | 4 | ||
| Age | 0.878 | 0.964 | ||||
| Median | 58.4 | 58.8 | 59.3 | 59.1 | ||
| Range | 35–78 | 29–81 | 37–78 | 29–83 | ||
| ECOG PS | 0.988 | 0.771 | ||||
| 0 | 17 | 18 | 14 | 13 | ||
| 1–2 | 14 | 16 | 10 | 11 | ||
| Tumor location | 0.608 | 0.745 | ||||
| Stomach | 21 | 25 | 18 | 17 | ||
| GEJ | 10 | 9 | 6 | 7 | ||
| Differential degree | 0.415 | 0.655 | ||||
| Poor/undifferentiated | 14 | 10 | 10 | 7 | ||
| Moderate | 9 | 12 | 7 | 8 | ||
| Well | 8 | 12 | 7 | 9 | ||
| AJCC stage | 0.151 | 0.505 | ||||
| III | 6 | 12 | 5 | 7 | ||
| IV | 25 | 22 | 19 | 17 | ||
| Initial CEA (ng/mL) | 0.158 | 0.308 | ||||
| Median | 69.5 | 18.4 | 40.9 | 21 | ||
| Range | 0.4–441.9 | 0.5–225.6 | 0.4–441.9 | 0.5–225.6 | ||
| Initial CA199 (U/mL) | 0.991 | 0.623 | ||||
| Median | 145.7 | 144.0 | 159.1 | 117.8 | ||
| Range | 1.3–1,600.0 | 0.6–1,571.0 | 1.3–1,600.0 | 0.8–1,000 | ||
| Surgery history | 0.638 | 0.763 | ||||
| No | 20 | 20 | 15 | 16 | ||
| Yes | 11 | 14 | 9 | 8 | ||
| Radiotherapy history | 0.615 | 0.416 | ||||
| No | 25 | 30 | 19 | 22 | ||
| Yes | 6 | 4 | 5 | 2 | ||
| Apatinib dosage (mg) | 0.796 | 0.350 | ||||
| <500 | 10 | 12 | 6 | 9 | ||
| ≥500 | 21 | 22 | 18 | 15 | ||
| Treatment lines | 0.531 | 1.000 | ||||
| Third-line | 7 | 10 | 6 | 6 | ||
| Subsequent-line | 24 | 24 | 18 | 18 | ||
Abbreviations: AJCC, American Joint Committee on Cancer; CA199, carbohydrate antigen 199; CEA, carcinoembryonic antigen; ECOG PS, Eastern Cooperative Oncology Group performance status; GEJ, gastroesophageal junction.